Clinical Trial Update: Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trial evaluating genotype-guided dosing of irinotecan based on UGT1A1 genotype in patients with metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Irinotecan (Irinotecan)

Snippet

Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Conditions: Metastatic Colorectal Cancer | Phase 2, Phase 3 | Status: COMPLETED